Migraine: Definitions, Mechanisms, and Treatment

Noack, H; Rothrock, John F.

doi:10.1097/00007611-199608000-00002

Cited by 8 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenesis of migraine has long been debated. The vascular theory proposes that vasoconstriction causes the focal neurologic symptoms and that vasodilation produces the pain 14 . In the central or neuronal theory, initial neuronal excitation is followed by a spreading depression within the brain neurons.…”

Section: Commentsmentioning

confidence: 99%

“…In the central or neuronal theory, initial neuronal excitation is followed by a spreading depression within the brain neurons. Vascular reactivity is secondary 14 . Although there are different theories of migraine pathogenesis, the SLE literature has relied on the vascular hypothesis to account for the high prevalence of migraine in patients with SLE.…”

Section: Commentsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Migraine in Patients With Systemic Lupus Erythematosus

et al. 2001

View full text Add to dashboard Cite

show abstract

Section: Commentsmentioning

confidence: 99%

Section: Commentsmentioning

confidence: 99%

Prevalence of Migraine in Patients With Systemic Lupus Erythematosus

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Our understanding of migraine's biogenesis has increased dramatically in recent years, evolving from a relatively simple vascular theory espoused by Wolff and Tunis [3] and others to the complex models of today. The most widely accepted current model proposes that migraine reflects genetically induced sensitization of the trigeminovascular system and central pathways that conduct, and perhaps even may generate, head pain [4,5]. In this instance, scientific theory has clear clinical relevance; animal models of migraine developed in accordance with current theory are now used routinely to test promising new therapies and validate existing therapies.…”

Section: Biologic Originsmentioning

confidence: 99%

What’s in a name? tension-type headache versus migraine

Rothrock

2001

Current Science Inc

Self Cite

View full text Add to dashboard Cite

For years clinicians and researchers have debated the nosology of headache generally and of "migraine" versus "tension-type headache" in particular, an exhaustive process that arguably has done little to improve patient management and clinical outcome. New research data now indicate that the migraine versus tension-type distinction indeed may possess some clinical use, because patients with migraine or "mixed" headache syndromes may respond differently to a specific therapeutic intervention than patients with "pure" tension-type headache. This variable response to treatment intervention would seem to imply that similarly distinctive biologies are generating the respective headache syndromes, but to date we have insufficient evidence to support that conclusion.

show abstract

“…The diagnosis and therapy of migraine have been reviewed [1][2][3][4][5], as has its epidemiology [6,7] and the economic impact of the management of migraine headache [8]. A number of reviews pertaining to the clinical experiences with sumatriptan (1) have appeared [9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Antimigraine agents: July 1995 - December 1996

Yevich

1997

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

The patent literature pertaining to agents for the treatment of migraine headache and related disorders has been reviewed for the period of July 1, 1995 to December 31, 1996. Included are patents on serotonergic agents, such as 5-hydroxytryptamine 1D (5-HT1D) receptor subtype agonists and 5-HT2 and 5-HT3 antagonists. Also covered are patents describing chemical entities that may be effective in migraine therapy based on their pharmacological actions as adrenergic agents, tachykinin receptor antagonists or inhibitors of nitric oxide synthetase (NOS). Selected references from the recent scientific literature have also been cited.Exp. Opin. Ther. Patents (1997) 7(5):511-521 2.1 5-HT 1 receptor subtype agonists Table 1 summarises the structural features and the types of supporting biological data for a variety of tryptamine and homotryptamine derivatives, which like sumatriptan, function as agonists at 5-HT1D or related serotonin receptor subtypes. These compounds bear a diversity of substituents at the indole 5-position (substituent X) and include chemotypes in which the basic nitrogen and/or its appending sidechain are incorporated into a ring. The in vitro biological data includes receptor binding affinities for 5-HT 1D and other 5-HT1 subtypes, as well as contractile activity upon vascular preparations, and was obtained using either recombinant human receptors or the appropriate brain or vascular tissues from various other species 511 511 1997 © Ashley Publicat ions Lt d.

show abstract

Migraine: Definitions, Mechanisms, and Treatment

Cited by 8 publications

References 0 publications

Prevalence of Migraine in Patients With Systemic Lupus Erythematosus

Prevalence of Migraine in Patients With Systemic Lupus Erythematosus

What’s in a name? tension-type headache versus migraine

Antimigraine agents: July 1995 - December 1996

Contact Info

Product

Resources

About